TWS119

Alias: TWS-119; TWS 119; TWS119
Cat No.:V0214 Purity: ≥98%
TWS119, apyrrolopyrimidine compound, is a novel, potent and selective/specific GSK-3β (Glycogen synthase kinase-3β) inhibitor with potentialusefulness for in vivo stem cell biology and therapy.
TWS119 Chemical Structure CAS No.: 601514-19-6
Product category: GSK-3
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
50mg
100mg
250mg
Other Sizes

Other Forms of TWS119:

  • TWS119 TFA
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

TWS119, a pyrrolopyrimidine compound, is a novel, potent and selective/specific GSK-3β (Glycogen synthase kinase-3β) inhibitor with potential usefulness for in vivo stem cell biology and therapy. It is capable of inducing neuronal differentiation and might be helpful for stem cell biology. It inhibits GSK-3β with an IC50 of 30 nM in a cell-free assay. When using mouse P19 EC cells, it is screened out of a library of pyrrolopyrimidines as a substance that selectively induces neuronal differentiation. TWS119 has a Kd value of 126 nM and strongly binds to GSK-3β. Combining TWS119 and GSK-3β modifies the complex's activity and causes subsequent transcriptional events that result in the induction of neurons. Additionally, TWS119 promotes neuronal differentiation of mESCs via a different mechanism as opposed to the conventional Wnt signaling pathway.

Biological Activity I Assay Protocols (From Reference)
Targets
GSK-3β (IC50 = 30 nM)
ln Vitro
Treatment of a monolayer of P19 cells with 1 μM TWS119 causes 30–40% cells to differentiate specifically into neuronal lineages based on counting of TuJ1 positive cells with correct neuronal morphology (up to 60% neuronal differentiation occurred through the standard EB formation protocol with concomitant TWS119 treatment). Surface plasmon resonance (SPR) measurements of TWS119's strong GSK-3-binding affinity (K D = 126 nM) and IC50 of 30 nM further support this conclusion. [1] WS119 is found to potently induces neuronal differentiation in both mouse embryonal carcinoma and ES cells. [2] TWS119 treatment towards hepatic stellate cells (HSC) leads to reduced b-catenin phosphorylation, induces nuclear translocation of b-catenin, elevates glutamine synthetase production, impedes synthesis of smooth muscle actin and Wnt5a, but promotes the expression of glial fibrillary acidic protein, Wnt10b, and paired-like homeodomain transcription factor 2c.[3] TWS119 causes a sharp up-regulation of the expression of Tcf7, Lef1, and other Wnt target genes like Jun, Ezd7 (encoding Frizzled-7), and Nlk (encoding Nemo-like kinase) in addition to triggering a rapid accumulation of -catenin (mean 6.8-fold increase by densitometry). TWS119 causes a dose-dependent reduction in T cell-specific killing and IFN-g release along with the maintenance of IL-2 production.[4] In polyclonally activated human T cells, treatment with TWS119 induces Wnt signaling, according to a recent study. Unlike control-activated T cells, which develop a CD45RO(+)CD62L(-) effector phenotype in a TWS119 dose-dependent manner, these T cells maintain a native CD45RA(+)CD62L(+) phenotype. Because cell division is prevented by TWS119-induced Wnt signaling, T cell expansion is reduced. Additionally, degranulation and IFN- production in response to T cell activation—which are both indicators of T cell effector function—are impaired. The inability of TWS119-treated T cells to use autocrine IL-2 for expansion may be the cause of the block in T cell division. This is because TWS119 treatment reduces the expression of the IL-2R. [5]
ln Vivo
A cell population that expressed low levels of CD44 and high levels of CD62L on the cell surface when 30 mg/kg of TWS119 is administered.[4]
Cell Assay
All rats are divided into four groups at random as follows: Sham group rats undergo the same surgical procedure, but the filament is not inserted, and they are given 1 mL of dimethyl sulfoxide (1% DMSO in saline); After MCAO, the rats in the vehicle group receive 1 mL of DMSO. At 4 hours after MCAO, the rats in the rtPA group receive rtPA (10 mg/kg, Actilyse®). At 4 hours after MCAO, the rats in the rtPA+TWS119 group receive intraperitoneal TWS119 (30 mg/kg, dissolved in 1 mL 1% DMSO).
Animal Protocol
All rats are divided into four groups at random as follows: Sham group rats undergo the same surgical procedure, but the filament is not inserted, and they are given 1 mL of dimethyl sulfoxide (1% DMSO in saline); After MCAO, the rats in the vehicle group receive 1 mL of DMSO. At 4 hours after MCAO, the rats in the rtPA group receive rtPA (10 mg/kg, Actilyse®). At 4 hours after MCAO, the rats in the rtPA+TWS119 group receive intraperitoneal TWS119 (30 mg/kg, dissolved in 1 mL 1% DMSO).
References

[1]. Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7632-7.

[2]. Nat Biotechnol. 2004 Jul;22(7):833-40.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C18H14N4O2
Molecular Weight
318.3294
Exact Mass
318.11168
Elemental Analysis
C, 67.92; H, 4.43; N, 17.60; O, 10.05
CAS #
601514-19-6
Appearance
Solid powder
SMILES
OC1=CC=CC(OC2=C3C(NC(C4=CC=CC(N)=C4)=C3)=NC=N2)=C1
InChi Key
VPVLEBIVXZSOMQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H14N4O2/c19-12-4-1-3-11(7-12)16-9-15-17(22-16)20-10-21-18(15)24-14-6-2-5-13(23)8-14/h1-10,23H,19H2,(H,20,21,22)
Chemical Name
3-((6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenol
Synonyms
TWS-119; TWS 119; TWS119
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~64 mg/mL (201.0 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
1% DMSO+30% polyethylene glycol+1% Tween 80: 30mg/mL (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.1414 mL 15.7070 mL 31.4139 mL
5 mM 0.6283 mL 3.1414 mL 6.2828 mL
10 mM 0.3141 mL 1.5707 mL 3.1414 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Status Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01087294 Active
Recruiting
Procedure: Allogeneic
stem cell transplant
Procedure: Leukapheresis
Leukemia, B-cell
Lymphoma, Hodgkins
National Cancer Institute
(NCI)
August 4, 2010 Phase 1
Biological Data
  • TWS119

    TWS119 activates Wnt signaling in CD8+ T cells. Nat Med. 2009 Jul;15(7):808-13.

  • TWS119

    Wnt signaling inhibits CD8+ T cell proliferation and effector differentiation

Contact Us